Analyzing XBiotech (NASDAQ:XBIT) & Nanobiotix (NASDAQ:NBTX)

Nanobiotix (NASDAQ:NBTX) and XBiotech (NASDAQ:XBIT) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Nanobiotix and XBiotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1	1	4	0	2.50
XBiotech	1	0	0	0	1.00

Nanobiotix presently has a consensus target price of $37.33, suggesting a potential downside of 14.27%. Given Nanobiotix’s stronger consensus rating and higher possible upside, research analysts plainly believe Nanobiotix is more favorable than XBiotech.

Volatility and Risk

Nanobiotix has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Earnings & Valuation

This table compares Nanobiotix and XBiotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87 million	59.79	-$27.11 million	N/A	N/A
XBiotech	N/A	N/A	-$45.54 million	($1.48)	-1.54

Nanobiotix has higher revenue and earnings than XBiotech.

Profitability

This table compares Nanobiotix and XBiotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
XBiotech	N/A	-31.62%	-30.29%

Summary

Nanobiotix beats XBiotech on 7 of the 10 factors compared between the two stocks.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.